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Background: Cystic fibrosis (CF) is the most common inherited disorder in Caucasian populations, with over 1400 mutations identified in the
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. Mutations in the CFTR gene may be also causative for CBAVD
(Congenital Bilateral Absence of the Vas Deferens). The type and distribution of mutations varies widely between different countries and/or
ethnic groups, and is relatively unknown in Iran. We therefore performed a comprehensive analysis of the CFTR gene in Iranian CF patients.
Methods: 69 Iranian CF patients, and 1 CBAVD patient, were analysed for mutations in the complete coding region, and its exon/intron
junctions, of their CFTR genes, using different methods, such as ARMS (amplification refractory mutation system)-PCR, SSCP (single
stranded conformation polymorphism) analysis, restriction enzyme digestion analysis, direct sequencing, and MLPA (Multiplex Ligation-
mediated Probe Amplification).
Results: CFTR mutation analysis revealed the identification of 37 mutations in 69 Iranian CF patients. Overall, 81.9% (113/138) CFTR genes
derived from Iranian CF patients could be characterized for a disease-causing mutation. The CBAVD patient was found to be homozygous
for the p.W1145R mutation. The most common mutations were p.F508del (ΔF508) (18.1%), c.2183_2184delAAinsG (2183AANG) (6.5%),
p.S466X (5.8%), p.N1303K (4.3%), c.2789+5GNA (4.3%), p.G542X (3.6%), c.3120+1GNA (3.6%), p.R334W (2.9%) and c.3130delA
(2.9%). These 9 types of mutant CFTR genes totaled for 52% of all CFTR genes derived from the 69 Iranian CF patients. Eight mutations,
c.406-8TNC, p.A566D, c.2576delA, c.2752-1_2756delGGTGGCinsTTG, p.T1036I, p.W1145R, c.3850-24GNA, c.1342-?_1524+?del,
were found for the first time in this study.
Conclusions: We identified 37 CFTR mutations in 69 well characterized Iranian CF patients, obtaining a CFTR mutation detection rate of
81.9%, the highest detection rate obtained in the Iranian population so far. These findings will assist in genetic counseling, prenatal diagnosis
and future screening of CF in Iran.
© 2007 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; CFTR; Mutations; Iran; Direct sequencing; c.2576delA; p.A566D; c.2752-1_2756delGGTGGCinsTTG; p.T1036I; p.W1145R;
CFTRdele9; c.406-8TNC; c.3850-24GNA1. Introduction
Cystic fibrosis (CF; MIM # 219700) is caused by muta-
tions in the Cystic Fibrosis Transmembrane conductance⁎ Corresponding author. Tel.: +98 21 88003812 ; fax: +98 21 88003811.
E-mail address: mzamani@sina.tums.ac.ir (M. Zamani).
1569-1993/$ - see front matter © 2007 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.jcf.2007.06.001Regulator (CFTR; #602421) gene that encodes a chloride
channel [1–3]. The CFTR gene is the seventh member of the
C subfamily of the ATP-binding cassette (ABC) transporter
gene super family (also called ABCC7) [4]. CFTR spans
approximately 190 kb of genomic DNA [5], is build up of 27
exons, and is located at chromosomal region 7q31.2 [6].
Cystic fibrosis (CF) is the most common severe autosomal
recessive disorder among white populations [7,8]. Cysticuropean Cystic Fibrosis Society.
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[9,10]. Apart from CF, CFTR mutations are also involved in
other diseases, such as CBAVD.
More than 1400 mutations have been reported in the
CFTR gene [11]. The distribution of these mutations varies
among different populations according to the geographical
and ethnic origin of patients [12,13]. A few mutations, such
as p.F508del, p.N1303K and p.G542X, are frequent world-
wide. Most mutations are however, isolated and have only
been detected in a few families. Deleterious mutations in the
CFTR gene can disrupt CFTR protein function by various
mechanisms based on the nature of mutation and on the
domain in which these alterations occur [14,15]. Regarding
the pancreatic status, there is a correlation between pheno-Table 1
Mutations identified in 138 CFTR genes of Iranian cystic fibrosis patients
Mutation a Exon/intron Nucleotide change
p.K68E E3 A to G at 334
c.406-8TNC I3 T to C at 406-8
c.406-3TNC I3 T to C at 406-3
p.R170H E5 G to A at 641
p.D192G E5 A to G at 707
p.R334W E7 C to T at 1132
c.1525-1GNA I9 G to A at 1525-1
p.F508del E10 Deletion of CTT from 1653
p.S466X E10 C to G at 1529
c.1677delTA E10 Deletion of TA from 1677
p.G542X E11 G to T at 1756
p.S549R E11 T to G at 1779
p.A566D E12 C to A at 1829
c.1898+1GNT I12 G→T at 1898+1
c.2183_2184delAAinsG E13 A to G at 2183 and deletion
c.2576delA E13 Deletion of A at 2576
c.2043delG E13 Deletion of A at 2043
c.2184insA E13 Insertion of A after 2184
p.R785X E13 C to T at 2485
c.2752-
1_2756delGGTGGCinsTTG
I14a/ Deletion of GGTGGC
E14b From 2752-1 to 2756 and
c.2789+5GNA I14b G to A at 2789+5
p.S945L E15 C to Tat 2966
c.3120+1GNA I16 G to A at 3120+1
c.3121-1GNA I16 G to A at 3121-1
c.3130delA E17a Deletion of A at 3130
p.T1036I E17a C to T at 3239
p.R1066C E17b C to T at 3328
p.L1077P E17b T to C at 3362
p.T1086I E17b C to T at 3389
p.R1162X E19 C to T at 3616
p.K1177X E19 A to T at 3361
c.3850-24GNA I19 G to A at 3850-24
p.N1303K E21 C to G at 4041
p.S1455X E24 C to G at 4496
c.186-?_296+?del E2 Large in frame deletion star
ending in intron 2
c.1342-?_1524+?del E9 Large in frame deletion st
ending in intron 9
c.406-?_1716+?del E4–E10 Large in frame deletion star
ending in intron 10
Mutations described for the first time appear in bold. Variants are described using t
frame shifts are reported at the cDNA level (c.), amino acid changes at the protein
a Mutations are named as recommended by the Human Genome Variation Socitype and genotype in patients sharing the same genotype
[16,17], but pulmonary disease can be variable.
Limited data of CFTR mutations in the Iranian popula-
tion, in which several ethnic groups are found, are available
[18,19]. Therefore we extensively characterized the CFTR
gene mutations in 69 well characterized Iranian CF patients.
2. Materials and methods
2.1. Patients and sampling
From 2002 to 2005, 69 unrelated families who had an
affected child with CF were referred to the Medical Genetics
division of the Children Medical Centre (CMC) hospital inConsequence No. of chromosomes
Lys to Glu at 68 1
mRNA splicing defect? 1
mRNA splicing defect 1
Arg to His at 170 1
Asp to Gly at 192 2
Arg to Trp at 334 4
mRNA splicing defect 2
Deletion of Phe at 508 25
Ser to stop at 466 8
Frame shift 2
Gly to stop at 542 5
Ser to Arg at 549 2
Ala to Asp at 566 2
mRNA splicing defect 2
of A at 2184 Frame shift 9
Frame shift 1
Frame shift 1
Frame shift 1
Arg to stop at 785 2
mRNA splicing defect 2
insertion TTG
mRNA splicing defect 6
Ser to Leu at 945 2
mRNA splicing defect 5
mRNA splicing defect 2
Frame shift 4
Thr to Ile at 1036 1
Arg to Cys at 1066 1
Leu to Pro at 1077 1
Thr to Ile at 1086 1
Arg to stop at 1162 2
Lys to stop at 1177 2
mRNA splicing defect? 1
Asn to Lys at 1303 6
Ser to stop at 1455 1
ting in intron 1, 1
arting in intron 8, 1
ting in intron 3, 2
he DNA and protein designation: intronic changes, deletions, insertions and
level (p.).
ety (http://www.genomic.unimelb.edu.au/mdi/).
Table 2
Genotype of CFTR genes in 53 Iranian patients
Genotype Exon/intron Number of
patients
p.F508del/p.F508del E10/E10 10
p.F508del/p.R1162X E10/E19 2
p.F508del/p.T1036I E10/E17a 1
p.F508del/p.R1066C E10/E17b 1
p.F508del/c.1342-?_1524+?del E10/E9 1
p.S466X/p.S466X E10/E10 4
c.2183_2184delAAinsG/
c.2183_2184delAAinsG
E13/E13 4
c.2183_2184delAAinsG/c.186-
?_296+?del
E13/E2 1
p.N1303K/p.N1303K E21/E21 2
p.N1303K/p.S945L E21/E15 1
p.N1303K/c.1677delTA E21/E10 1
p.G542X/p.G542X E11/E11 2
p.G542X/c.2789+5GNA E11/I14b 1
c.3120+1GNA/c.3120+1GNA I16/I16 2
c.3120+1GNA/c.3121-1GNA I16 1
c.3121-1GNA/p.T1086I I16/E17b 1
c.3130delA/c.3130delA E17a/E17a 2
p.D192G/p.D192G E5/E5 1
p.R334W/p.R334W E7/E7 1
p.R334W/p.S945L E7/E15 1
p.R334W/p.L1077P E7/E17b 1
c.1525-1GNA/c.1525-1GNA I9/I9 1
p.S549R/p.S549R E11/E11 1
p.A566D/p.A566D E12/E12 1
c.1898+1GNT/c.1898+1GNT I12/I12 1
c.2576delA/p.S1455X/ E13/E24 1
c.2184insA/c.1677delTA E10/E13 1
p.R785X/p.R785X E13/E13 1
c.2752-1_2756delGGTGGCinsTTG/
c.2752-1_2756delGGTGGCinsTTG
I14a/E14b 1
c.2789+5GNA/c.2789+5GNA I14b/I14b 1
p.K1177X/p.K1177X E19/E19 1
c.406-?_1716+?del/c.406-?_1716+?del E4-E10/E4-E10 1
Total 53
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history, were collected. The diagnosis of CF was routinely
carried out by clinical features consistent with a CF pheno-
type together with an elevated sweat chloride concentration.
Diagnostic criteria for 65 subjects were based on repeated
positive sweat chloride tests (diagnosis was made based on
pilocarpine method with values N60 mmol/l) and on typical
findings of pulmonary/gastrointestinal disease. Five patients
with abroad spectrum of respiratory diseases or undefined
pancreatic and borderline (40–60 mmol/l) sweat chloride
values were analysed. The patients, 38 males and 31 females,
originated from Iran (at least living for three generations in
Iran). Also 1 CBAVD patient was included in the study.
2.2. Mutation detection
Genomic DNA was extracted from peripheral blood leu-
kocytes using the salting out precipitation method. Mutations
were detected as follows:
In a first phase, all subjects were analyzed with an am-
plification refractory mutation system assay (ARMS-PCR),
as described by Ferrie et al. [20], detecting the following
mutations: p.F508del, p.N1303K, p.G542X, c.1717-1GNA,
p.R553X, p.W1282X, p.G551D, c.621+1GNT, c.I507del
and p.R560T.
In a second phase, single stranded conformation poly-
morphism (SSCP) analysis of exons 3, 7, 10, 11 and 17b,
including both exon/intron junctions, of the CFTR gene was
performed in patients in whom no mutation could be iden-
tified on one or both CFTR genes in the first phase. In
samples, whose PCR products showed a different mobility
from those of the reference control, the relevant PCR pro-
ducts were analysed by direct sequencing.
In a third phase, for the patients in whom a mutation could
still not be identified on one or both of CFTR genes, complete
sequencing of the CFTR coding region and its exon/intron
junctions was aimed. All patients were sequenced together,
exon by exon, starting with exons that harbor the highest
number of mutation events worldwide. If a mutation was
identified, so that a mutation on both CFTR genes of a patient
was characterized, the remainder exons were not analysed
further, except for some missense mutations in order to detect
or exclude the presence of other mutations in cis. Amplifi-
cation of all 27 CFTR exons, including flanking intronic
regions, was performed using CFTR gene specific primers,
which are commonly used in many studies for CFTR analysis
[21,22]. The PCR products were purified using small
purification columns. Amplicons were sequenced in both
directions using the ABI PRISM Big Dye terminator cycle
sequencing reaction kit (v3.1) (Applied Biosystems) accord-
ing to the protocol of the manufacturer. The samples were run
on an ABI-3100 Genetic Analyzer (Applied Biosystems).
The sequences were analyzed with the SeqScape software
V2.5 (Applied Biosystems).
In a fourth phase, the 3849+10 kbC→T mutation was
screened by HphI restriction enzyme analysis as describedby Highsmith et al. [23], in subjects in whom no CFTR
mutation was found on both CFTR genes.
In a final phase, large deletions and/or duplications of
CFTR exons were searched for with the CFTR Vs03 MLPA
assay (MRC-Holland b.v.) in samples that remained incom-
pletely characterized for a CFTR mutation, according to the
protocol provided by the manufacturer. In each reaction,
about 300 ng DNA was denatured and hybridized with
SALSA probe-mix. After the ligation reaction, 33 cycles of
PCR were performed; 20 s at 95 °C, 30 s at 60 °C and 1 min
at 72 °C, the reaction was initiated by 7 min incubation at
95 °C and terminated by a 20 min incubation at 72 °C. The
samples were analyzed on an ABI-3100 Genetic Analyzer
(Applied Biosystems).
3. Results
A total of 69 unrelated CF patients (38 male and 31
female; aged between 2 months and 15 years) of Iranian
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tions in the CFTR gene, for the presence of the deep
intronic 3849+10 kbC→T mutation, and large deletions/
duplications. Screening of the samples for ten mutations
with an ARMS-PCR assay only revealed the identification
of three mutations: p.F508del was found in 25 (18.1%)
alleles, p.N1303K in six (4.3%) alleles, and p.G542X in
five (3.6%) alleles (Table 1), the remainder mutations in the
CFTR coding region, and its exon/intron junctions, were
found by sequencing and the MLPA assay, which are given
in Table 1. The intronic 3849+10 kbC→T mutation was
not found. Three large deletions c.186-?_296+?del, c.1342-
?_1524+?del and c.406-?_1716+?del were found. The
c.406-?_1716+?del mutation was found in homozygous
state in a consanguine family, and was already obvious
during sequence analyses, since PCR fragments aiming at
amplification of exons 4 through 10 failed to be amplified.Fig. 1. Geographical distribution of CFTR mutations in Iran. The number of CFTR
mutations described for the first time in this study are given in bold. Most of theNo effort was undertaken to precisely locate the deletion
borders of these deletions. A total of 37 different small
mutations, scattered all over the CFTR gene, were identified:
besides the small deletion p.F508del, 12 missense mutations,
9 splicing defects, 6 frame-shift mutations, 6 nonsense
mutations and 3 large deletions were detected.
A total of 38 patients (55%) were homozygous for a CFTR
mutation. This can be explained by the high consanguinity
that is observed in the Iranian population. In the present study,
60% of patients were born from consanguine families. The
degree of relationship between parents of these CF patients
was mostly 3. Fifteen patients (21.7%) were compound
heterozygous for a CFTRmutation. Thus in 53 patients out of
69 patients a mutation could be identified on both CFTR
genes (Table 2). In 7 patients a mutation could only be found
on one CFTR gene (Table 4). In 9 CF patients, no disease-
causing CFTR mutation at all was found (Table 5).genes carrying a specific mutation is given. 1U: unknown mutation. Novel
Centre, East and South East of Iran are desert and hardly populated.
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mutation, accounting for 18.1% of the CFTR mutations. The
p.F508del mutation was found in 15 patients and 10 of them
were homozygous, of which 7 were from consanguine fam-
ilies. The patients that carried the p.F508del mutation were
from different parts and ethnic groups of Iran. Eight other
mutations were found with a frequency greater than 2%:
c.2183_2184delAAinsG (6.5%), p.S466X (5.8%), p.N1303K
(4.3%), c.2789+5GNA (4.3%), p.G542X (3.6%), c.3120+
1GNA (3.6%), p.R334W (2.9%), and c.3130delA (2.9%).
Fifteen mutations were only found once and 13 mutations
were found twice, and accounted together respectively for
10.9% and 18.8% of the CFTR genes of the studied patients.
IVS8-5T was not found at all in our patients.
In the five patients with a broad spectrum of respiratory
diseases or undefined pancreatic disease and borderline
(40–60 mmol/l) sweat chloride values, the heterozygous
state for 1 mutation was found, i.e. the c.3499+37GNA,
c.2789+5GNA, c.406-8TNC, c.3850-24GNA, and the
p.I148T polymorphism.
Overall, 8/37 mutations were novel mutations, first de-
scribed in this study (Fig. 1).
The c.2576delA frame-shift mutationwas found in exon 13
of the CFTR gene, and will result in a stop codon five codons
downstream of themutation site. It was found once in a patient
that carried S1455X in compound heterozygosity. CF was
diagnosed at the age of 4 years and the patient has a classical
CF phenotype. The patient originates from the Markazi pro-
vince, located between the centre and west of Iran.
The p.A566D mutation is located in exon 12 and was
found in homozygous state in 1 consanguineous patient who
has a classical CF phenotype. He originated from the Esfahan
province in the centre of Iran.
The c.2752-1_2756delGGTGGCinsTTG mutation is a
complex mutation, in which six nucleotides (GGTGCC)
are deleted from 2752-1 (intron14a) until nucleotide 2756
(exon14b) and replaced by three nucleotides (TTG). The
mutation disrupts the consensus splice acceptor site at the
3´ end of intron 14a. The mutation was found in one con-
sanguineous patient who was homozygous for this mutation.
She has typical CF. She is from the Khuzestan province in
the south west of Iran.
The p.T1036I missense mutation is located in exon 17a,
and was found in one patient who carried p.F508del in
compound heterozygosity. He has typical CF. He is from the
Qazvin province, located between the centre and north-west
of Iran.
The c.1342-?_1524+?del was detected with the MLPA
assay. It's caused by a deletion of exon 9 and the flanking
regions in introns 8 and 9; however the extent of the deletion
is not known. The mutation was found once in a patient with
typical CF disease, who carried p.F508del mutation in com-
pound heterozygosity. He is from the Zanjan province.
The c.406-8TNC mutation is located in intron 3 of the
CFTR gene. It might affect splicing, which can only be
proved after functional studies, and therefore it is not clear ifit is a CF-causing disease mutation. The patient had a bor-
derline sweat test and originates from the Esfahan province
in the center of Iran.
c.3850-24GNA was found once in intron 19 of CFTR
gene. It is not clear if it affects splicing and therefore if it is a
disease causing mutation.
The CBAVD patient, without pulmonary disease, was
homozygous for the p.W1145R mutation. He originates from
the Azarbayjan-e Sharqi province in the north-west of Iran.
4. Discussion
There are only a few reports that describe the distribution
and frequency of CFTR gene mutations in Iran [18,19]. In
the present study, we analyzed the complete coding region
and exon/intron junctions of the CFTR gene, and the deep
intronic 3849+10 kb CNT mutation, in our patients. We
found 37 different CFTR mutations, which explain 81.9% of
the mutations in the CFTR genes derived from 69 unrelated
Iranian CF patients.
The overall distribution of CFTR mutations in the Iranian
population considerably differs from those reported in the
neighboring countries Pakistan, India, Turkey and Arabian
countries [13,24–28]. The Iranian patients were from 44
cities located in different geographic areas and different
ethnic groups in Iran, and the distribution and frequency of
the most commonCFTRmutations varies among these ethnic
groups and geographic areas.
The p.F508del mutation had a frequency of 18.1% in our
Iranian CF patients, this in contrast with European and other
populations where the frequency of the p.F508del is more
than 50% [24,29–32]. The geographical distribution of the
p.F508del shows a decreasing frequency from the Northwest
to the Southeast of Europe [13,24,29,31,33,34]. The Islamic
Republic of Iran is located to the Southeast of Turkey, and
based on this gradient, the observed lower frequency of the
p.F508del is in agreement with this observation.
The c.2183_2184delAAinsG mutation was the second
most common mutation in Iran with a mean frequency
6.5%. It was detected in five patients, of which 4 were
homozygous and of which in turn 2 were of consanguineous
families. They were from Lorestan, Hamadan, Tehran, Fars
and Azarbayjan-e Sharqi provinces (Lur, Persian and Azeri).
The c.2183_2184delAAinsG mutation is also more frequent
in Turkey (2.5–4.9%) and the northeast of Italy (9.3%)
[24,27,28,35].
The third most prevalent mutation in Iran was p.S466X. It
was found in 5.8% of the CFTR genes from Iranian CF
patients, and was only observed in homozygous state. These
4 patients were from Tehran, Khorasan, Hamadan and Mar-
kazi provinces. The parents of these patients all had con-
sanguine marriages, however since that the mutation was
present in families from different regions; it seems to be a
relative frequent mutation in Iran. This mutation is rare
worldwide, but has a frequency of 0.5% in Serbia and
Montenegro [36,37].
Table 3
CFTR mutation panel recommended for screening in Iranian CF patients
Mutation Number of chromosomes Frequency
p.F508del 25 18.1%
c.2183_2184delAAinsG 9 6.5%
p.S466X 8 5.8%
p.N1303K 6 4.3%
c.2789+5GNA 6 4.3%
p.G542X 5 3.6%
c.3120+1GNA 5 3.6%
p.R334W 4 2.9%
c.3130delA 4 2.9%
Total 72 52.0%
Table 4
Clinical features and some polymorphisms in 7 Iranian patients; in these p
Genotype PI/PS Sweat (Cl−) TGm
p.K68E/U⁎ PI 80 TG10
c.406-8TNC/U PI 50 TG12
c.406-3TNC/U PI 90 TG11-
p.R170H/U PS 80 TG11-
c.3850-24GNA/U PI 55 TG11-
c.2789+5GNA/U PI 50 TG11-
c.2043delG/U PS 70 TG12
⁎Unknown mutations; PS, indicates pancreatic sufficient; PI, pancreatic su
Table 5
Clinical features and some polymorphisms in 9 Iranian patients; in these p
Mutation status⁎ PI/PS PD Sweat (Cl−)
p.G576A+/p.R668C+ PS PD 90
p.G576A+/p.R668C+ PS PD 70
p.G576A+/p.R668C+ PS PD 60
p.I148T+/U⁎ PI PD 80
p.I148T+/U⁎ PI N 50
c.3499+37GNA+/U⁎ PS PD 55
U⁎/U⁎ PS PD 75
U⁎/U⁎ PS PD 110
U⁎/U⁎ PS PD 70
⁎Unknown mutations; + non-disease causing mutations; PD, pulmonary d
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were p.N1303K (4.3%) and c.2789+5GNA (4.3%). These
two mutations were found in different geographical areas
and ethnic groups in the Iranian population. Both of them
were detected twice in homozygous state, because of con-
sanguinity, and twice in compound heterozygous state. The
p.N1303K mutation is found worldwide at a rather high
frequency (1.3%). It was reported as a common mutation in
the Mediterranean region and reaches its highest frequency
(17.2%) in Tunisia [38]. The c.2789+5GNA mutation ac-
counts for more than 1% of CF mutations worldwide (20).
The p.G542X mutation accounts for 2.4% of the CFTR
mutations worldwide [13,21]. In this study, the frequency of
this mutation was found on 3.6% of the CFTR genes. Two
patients carried p.G542X in homozygous state, of which oneatients
Tn (In8
-T7_TG
-T7_TG
T7_TG
T7_TG
T7_TG
T7_TG
-T7_TG
fficient
atients
TGm
TG11-
TG12-
TG10-
TG11-
TG10-
TG11-
TG11-
TG11-
TG10-
isease; Pwas consanguineous, and one was compound heterozygous
with c.2789+5GNA.
The 3120+1GNA mutation is known as the African CF
mutation [39], and has a frequency of 12.2% in African–
American people [24,25,40]. Here, it was found in three
males. Two patients were homozygous for this mutation,
while the third patient carried the c.3120+1GNA mutation
in compound heterozygosity with the 3121-1GNA mutation.
The two homozygous patients were from Khuzestan and
Hamadan provinces (Southwest and West of Iran) and the
third one from Khuzestan province.
Based on the observed frequency of the different muta-
tions, i.e. mutations having an allele frequency of N2% in
Iranian CF patients, a panel of 9 mutations is recommended
for CFTR mutation analysis in Iran (Table 3). These 9
mutations will detect 52% of the disease-causing mutations
in Iran. Commercial tests, such as the ARMS test (13 muta-
tions kit), the INNO-LiPA assay (29 mutations) and OLA
assay (31 mutations) will respectively only detect 30.4%,
41.3%, and 44.2% of the CFTR mutations in Iran [41]. The
molecular basis of CF disease in patients in whom a CFTR
mutation could not be identified on both CFTR genes is not
clear. In 7 patients, one CFTR mutation was found, which
indicates at least some CFTR involvement in these patients
(Table 4). In 9 CF patients, no disease-causing CFTR muta-
tion at all was found, thus these patients are suspected of
having CF (Table 5).
Possible explanations for failure to detect all mutations
are: the mutations that are in intron sequences far from codinga mutation could only be found on one CFTR gene
) GATT (In6a) 1001+11 (In6b) M470V
10-T7 GATT 7/7 C A
11-T7 GATT 6/7 C A/G
11-T7 GATT 7/7 C G
10-T7 GATT 7/7 C A/G
11-T7 GATT 7/7 C G
10-T7 GATT 7/7 C A/G
10-T7 GATT 6/7 C A
.
no disease-causing CFTR mutation at all was found
Tn (In8) GATT (In6a) 1001+11 (In6b) M470V
T7_TG10-T7 GATT 7/7 C A/G
T7_TG10-T7 GATT 6/7 C G
T7_TG10-T7 GATT 7/7 C A
T7_TG10-T7 GATT 7/7 C A/G
T9_TG10-T9 GATT 6/6 T A
T7_TG10-T7 GATT 7/7 C A/G
T7_TG11-T7 GATT 7/7 C G
T7_TG11-T7 GATT 7/7 C G
T7_TG10-T7 GATT 7/7 C A
S, indicates pancreatic sufficient; PI, pancreatic sufficient; N, normal.
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CNT mutation) or distant regulatory sequences were not
detected; the loci other than CFTRmay be involved in disease
in some patients; possibly CF-like disease may be more
prominent in Iran and neighboring countries, so that these
patients might be of interest for the identification of another
genetic basis of their disease and finally the diagnosis of
cystic fibrosis may be incorrect. A Turkish study also had a
high percentage of CFTR genes (47.5%) from CF patients
where a mutation could not be identified [28].
In summary, we comprehensively analysed the CFTR
gene in Iranian CF patients, and obtained a mutation sen-
sitivity of 81.9%.
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